Press release
Urothelial Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the treatment Landscape. Click here to read more @ Urothelial Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Urothelial Carcinoma Pipeline Report
* In August 2025, Astellas Pharma Global Development, Inc . announced a study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer.
* In August 2025, Merck Sharp & Dohme LLC conducted a substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
* In August 2025, Seagen organized a study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
* In August 2025, AbbVie conducted a study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio.
* DelveInsight's Urothelial Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
* The leading Urothelial Carcinoma Companies such as MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development , and others
* Promising Urothelial Carcinoma Pipeline Therapies such as Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat , and others.
Discover groundbreaking developments in Urothelial Carcinoma therapies! Gain in-depth knowledge of key Urothelial Carcinoma clinical trials, emerging drugs, and market opportunities @ Urothelial Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Urothelial Carcinoma Emerging Drugs Profile
* Pemazyre (pemigatinib): Incyte
Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.
* Cetrelimab: Janssen Research and Development
Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.
Stay informed about the Urothelial Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Urothelial Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Urothelial Carcinoma Companies
MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development , and others.
Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intranasal
* Intrathecal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
* Transdermal
Urothelial Carcinoma Products have been categorized under various Molecule types such as
* Antisense oligonucleotide
* Gene therapy
* Hormones
* Neuropeptides
* Oligonucleotides
* Small Molecule
* Triglyceride
Transform your understanding of the Urothelial Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of Urothelial Carcinoma Pipeline Report
* Coverage- Global
* Urothelial Carcinoma Companies- MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development , and others.
* Urothelial Carcinoma Pipeline Therapies- Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others
* Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research-Access the Full Urothelial Carcinoma Pipeline Analysis Today! @ Urothelial Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Introduction
2. Urothelial Carcinoma Executive Summary
3. Urothelial Carcinoma: Overview
4. Urothelial Carcinoma Pipeline Therapeutics
5. Urothelial Carcinoma Therapeutic Assessment
6. Urothelial Carcinoma- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase III)
8. Cetrelimab: Janssen Research and Development
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Vactosertib: MedPacto
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. MV NIS: Vyriad
18. Drug profiles in the detailed report.....
19. Preclinical Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report.....
22. Inactive Products
23. Urothelial Carcinoma Key Companies
24. Urothelial Carcinoma Key Products
25. Urothelial Carcinoma- Unmet Needs
26. Urothelial Carcinoma- Market Drivers and Barriers
27. Urothelial Carcinoma- Future Perspectives and Conclusion
28. Urothelial Carcinoma Analyst Views
29. Urothelial Carcinoma Key Companies
30. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=urothelial-carcinoma-pipeline-outlook-report-2025-key-40-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/urothelial-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Urothelial Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4144539 • Views: …
More Releases from ABNewswire
DermaStation Skin Clinic strengthens its hair loss treatment offering
The Delhi-based skin clinic offers the most advanced hair loss treatment that ensures healthier hair regrowth and improved density.
In view of the growing concerns over progressive hair fall and pattern baldness, DermaStation, a popular dermatology clinic in Delhi, enhances its Platelet Rich Plasma Therapy for better and lasting results.
The move to offer advanced platelet rich plasma treatment [https://www.dermastation.com/blog/platelet-rich-plasma-treatment-in-delhi-a-complete-guide-to-prp-therapy/] and comprehensive treatment is in line with DermaStation's commitment to provide finest…
Grand Prairie-Based Cannon System Design Addresses Rising IT Networking Demands …
Cannon System Design, a Grand Prairie technology firm established in 2019, provides IT infrastructure and security solutions across the DFW region, serving schools, hospitals, churches, and businesses with local expertise.
As businesses and institutions across the Dallas-Fort Worth area face increasing technological demands, Cannon System Design [https://www.cannonsystem.design/] has positioned itself as a reliable provider of comprehensive technology solutions. Since launching operations in 2019, the Grand Prairie-based company has been serving schools,…
CLAIMED BY GOD DESIGNS Announces 2026 Expansion Following Breakthrough Holiday P …
After achieving record holiday sales, CLAIMED BY GOD DESIGNS prepares major 2026 expansion plans to meet growing demand for faith-based fashion that empowers believers worldwide. The brand's scripture-rooted designs and innovative approach to Christian lifestyle retail continue attracting new generations of faithful consumers seeking authentic, stylish expressions of belief.
CLAIMED BY GOD DESIGNS is leveraging extraordinary holiday season success to launch ambitious expansion plans for 2026, positioning the brand to meet…
Burbank Chimney Services Advises Homeowners on Year-Round Chimney Safety
Burbank Chimney Services is advising homeowners to take a proactive approach to chimney safety during the winter heating season, when increased fireplace use can reveal underlying issues within chimney and ventilation systems. Industry professionals say colder temperatures and heavier usage often make debris accumulation, moisture intrusion, and airflow problems more noticeable and potentially hazardous.
Homeowners scheduling a Chimney Sweep [https://burbankchimneyservices.com/] are encouraged to arrange inspections during winter months, when creosote buildup,…
More Releases for Urothelial
Rising Bladder Cancer Cases Fueling Growth In The Urothelial Carcinoma Treatment …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Urothelial Carcinoma Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market segment dedicated to treating urothelial carcinoma has experienced swift expansion lately, projected to increase its value from 2.86 billion USD in 2024 to 3.36 billion USD the following year, reflecting a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Urothelial Cancer Drugs Market for Bladder and Urinary Tract Tumors | Driven by …
Urothelial Cancer Drugs market is expected to grow at a CAGR Of 21.2% during the forecast period 2024-2031.
The Urothelial Cancer Drugs Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm…
Major Market Shift in Urothelial Carcinoma Treatment Industry: Innovations In Ur …
What Is the Forecasted Market Size and Growth Rate for the Urothelial Carcinoma Treatment Market?
In the recent years, there has been a swift escalation in the size of the urothelial carcinoma treatment market. It is projected to expand from $2.86 billion in 2024 to $3.37 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 18.0%. The growth during the past period can be credited to an upsurge in…
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
